Nobel Prize in Medicine 2026: How Algae Gave Neuroscience a Light Switch for the Brain

The 2026 Nobel Prize in Physiology or Medicine has been awarded jointly to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics. The Nobel Assembly at Karolinska Institutet announced the prize on Monday 5 October. The three laureates share 12 million Swedish kronor (about $1.2 million) equally.

Optogenetics lets researchers switch selected nerve cells on or off in a living brain using light. The method began with a single-celled alga that swims towards light, and it has since become a standard tool for testing how specific circuits shape memory, emotion, sleep and behaviour.

In brief

Optogenetics researchers win Nobel Prize in Physiology or Medicine

Laureates: Karl Deisseroth (Stanford University, born 1971), Peter Hegemann (Humboldt University of Berlin) and Georg Nagel (University of Würzburg, born 1953).
Awarded for: discoveries concerning light-gated ion channels and optogenetics.
Why it matters: it moved neuroscience from observing which brain cells are active to testing, directly, what those cells do.
Still a research tool: clinical uses are at an early stage.

From a swimming alga to a molecular switch

The story starts with Chlamydomonas, a single-celled green alga that senses light with an eyespot. Hegemann's curiosity about how it does so led his group to discover channelrhodopsin-1, the first direct evidence of a light-gated ion channel. About a year later, a team led by Nagel showed that a second protein, channelrhodopsin-2, behaved differently: it was activated by blue light and worked as a broad cation channel. The results were published in 2003.

The key point was that each protein works as a single unit. It senses light and forms the channel that lets charged ions cross the cell membrane. Hegemann and Nagel also found that other cells given the protein could themselves be made sensitive to light. Neurons communicate through electrical signals, so a protein that turns light into an electrical current was an obvious candidate for controlling them.

The idea of controlling one cell type with light was not new. Francis Crick had speculated about it, though he called his own idea far-fetched. What was missing was a molecule that could do the job.

Making neurons answer to light

Deisseroth's laboratory at Stanford took the next step. Using a construct supplied by Nagel, the group introduced the channelrhodopsin-2 gene into rat nerve cells and triggered nerve signals with blue light on a millisecond timescale. The result was published in Nature Neuroscience in 2005. Ed Boyden was first author and Feng Zhang second, with Ernst Bamberg, Nagel and Deisseroth also credited.

Two years later, Deisseroth's group made the switch work in the brains of living mice. The method combines two ingredients. Genetics makes only chosen cell types produce a light-sensitive protein, an opsin, and optics delivers light, often through a thin optical fibre, to switch those cells on or inhibit them, depending on the opsin.

Its advantage over older tools is specificity. Electrodes stimulate whatever cells are nearby, and drugs act broadly and slowly. Optogenetics targets defined cell types and works at the speed of the brain's own signalling.

From correlation to cause

Before optogenetics, much of neuroscience was correlational. Researchers could see that a brain region became active during fear or a decision, but not whether that activity caused the behaviour. With optogenetics, a scientist can activate a defined set of neurons and watch what follows, then silence them and see whether the behaviour disappears.

The Nobel Committee's chair, Per Svenningsson, said the method offers ways of mapping the brain that researchers could once only dream of. Early applications examined the neurons that drive transitions from sleep to wakefulness. The Nobel committee also highlights work in which Deisseroth, with Susumu Tonegawa, activated an engram, the pattern of neural pathways formed when a memory is created. Researchers also use the method to study circuits for fear, reward, movement and learning, and the circuits that go wrong in disease.

What it means for medicine

Optogenetics itself remains primarily a research tool. Using it in people requires genetically modifying cells so they respond to light and getting light to the right tissue. The eye is the most advanced route, because light already reaches the retina.

In 2021, researchers led by José-Alain Sahel and Botond Roska reported in Nature Medicine that a blind patient with retinitis pigmentosa regained partial vision. The patient received a gene therapy encoding a channelrhodopsin, and used light-stimulating goggles. It was the first demonstration of clinical benefit from optogenetics and involved one patient. The study's lead author noted that it would take time before such a therapy could be offered to patients.

A prize with many contributors

Nobel Prizes can be shared by at most three people, and optogenetics drew on many hands. The Brain Prize in 2013 went to six scientists: Ernst Bamberg, Ed Boyden, Deisseroth, Hegemann, Gero Miesenböck and Nagel. Deisseroth and Boyden each received a Breakthrough Prize in Life Sciences, and Deisseroth, Hegemann and Miesenböck shared the 2022 Louisa Gross Horwitz Prize. Those earlier awards reflect how widely the field's founders were already recognised.

Deisseroth told reporters the announcement was a complete surprise. He has said that optogenetics grew out of basic science that was not explicitly medicine-related, and that its relevance to illness appeared only years later.

The wider significance

For much of its history, brain science has relied on anatomy, then on imaging that reveals patterns of activity. Optogenetics added the ability to intervene in circuits with cellular precision, and to view behaviour as the product of interacting networks rather than isolated regions.

None of this means the brain has been solved. Optogenetics will not answer questions about perception or consciousness on its own, but it has given researchers a direct way to test what individual circuits do. The prize recognises a route from basic curiosity about algae to a tool that changed how the brain is studied.

Key facts

Prize: Nobel Prize in Physiology or Medicine 2026
Laureates: Karl Deisseroth, Peter Hegemann, Georg Nagel
Awarded for: discoveries concerning light-gated ion channels and optogenetics
Key molecules: channelrhodopsin-1 and channelrhodopsin-2, from the alga Chlamydomonas reinhardtii
Key milestones: channelrhodopsin papers (2003); light-controlled firing in cultured neurons (2005); living mice (2007)
Prize amount: SEK 12 million, shared equally

Sources